Absence of copy number gain of EGFR: A possible predictive marker of long‐term response to afatinib

Treatment efficacy of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‐TKI) is diverse even in non‐small cell lung cancer (NSCLC) patients with EGFR activating mutations. Extraordinary long‐term responses sustained over 3 years among NSCLC patients treated with afatinib, an EGFR‐TKI,...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakamura, Tomomi, Sato, Akemi, Nakashima, Chiho, Abe, Tomonori, Iwanaga, Kentaro, Umeguchi, Hitomi, Kawaguchi, Atsushi, Sueoka‐Aragane, Naoko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9986088/
https://www.ncbi.nlm.nih.gov/pubmed/36382532
http://dx.doi.org/10.1111/cas.15655

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9986088/
https://www.ncbi.nlm.nih.gov/pubmed/36382532
http://dx.doi.org/10.1111/cas.15655

Ejemplares similares